SCHEMBL20825237

SCHEMBL20825237

CC(C)C[C@@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@H](CCc1ccccc1)C(=O)O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TMPRSS11D O60235 2/20 0.75
CTRL P40313 2/20 0.75
PSMB5 P28074 14/20 0.74
CYP3A4 P08684 2/20 0.74
CYP3A5 P20815 2/20 0.74
CYP3A7 P24462 2/20 0.74
CYP3A43 Q9HB55 2/20 0.74
PSMB9 P28065 2/20 0.74
PSMB8 P28062 2/20 0.74
PSMB10 P40306 2/20 0.74
PSMB2 P49721 2/20 0.74
PSMB11 A5LHX3 1/20 0.74
PSMD11 O00231 1/20 0.74
PSMD12 O00232 1/20 0.74
PSMD14 O00487 1/20 0.74
PSMA7 O14818 1/20 0.74
PSMD3 O43242 1/20 0.74
CTSB P07858 1/20 0.74
PSMC3 P17980 1/20 0.74
PSMB1 P20618 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19851642 1.00 TMPRSS11D (0.75) TMPRSS11DCTRLPSMB5CYP3A4CYP3A5
SCHEMBL15634574 0.97 TMPRSS11D (0.73) TMPRSS11DCTRLPSMB5CYP3A4CYP3A5
SCHEMBL17452276 0.97 TMPRSS11D (0.73) TMPRSS11DCTRLPSMB5CYP3A4CYP3A5
SCHEMBL15634572 0.97 TMPRSS11D (0.73) TMPRSS11DCTRLPSMB5CYP3A4CYP3A5
SCHEMBL31192812 0.97 TMPRSS11D (0.73) TMPRSS11DCTRLPSMB5CYP3A4CYP3A5
SCHEMBL23616318 0.95 CTRL (0.80) TMPRSS11DCTRLPSMB5CYP3A4CYP3A5
SCHEMBL20825238 0.95 CTRL (0.80) TMPRSS11DCTRLPSMB5CYP3A4CYP3A5
SCHEMBL8075093 0.95 CTRL (0.80) TMPRSS11DCTRLPSMB5CYP3A4CYP3A5
SCHEMBL8080983 0.95 CTRL (0.80) TMPRSS11DCTRLPSMB5CYP3A4CYP3A5
SCHEMBL18257553 0.95 CTRL (0.80) TMPRSS11DCTRLPSMB5CYP3A4CYP3A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10364269-B2 Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof LAURUS LABS LIMITED (IN) 2019-07-30 US disclosed
US-20190085026-A1 AN IMPROVED PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF Laurus Labs Ltd. (IN) 2019-03-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190085026-A1 AN IMPROVED PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF PRCP, SF3B5, GBA1 TMPRSS11D 459/4885CTRL 7/4885PSMB5 28/4885
US-10364269-B2 Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof SF3B5, PRCP, GBA1 TMPRSS11D 513/4885CTRL 10/4885PSMB5 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.